Skip to main content

J&J To Be Sole Responsible In Talc Punitive Damages Trial

J&J To Be Sole Responsible In Talc Punitive Damages Trial

J&J To Be Sole Responsible In Talc Punitive Damages Trial

Introduction

Johnson & Johnson (J&J) will face a new trial on the issue of punitive damages, following the $12 million awarded in compensatory damages to a plaintiff on June 12, who was diagnosed with mesothelioma due to exposure to talcum powder. Recently, Judge Frank Roesch rejected the request from J&J to involve Colgate and Avon in punitive damages.

During a hearing in Oakland, California, the judge set July 8 for the opening argument and rejected J&J's request to wait until it has filed an expedited appeal. Also, the judge rejected J&J's argument that the new jury should be told about the decision from the previous jurors that J&J and Colgate-Palmolive, both were at 40% fault, with the remaining 20% against Avon, which made up the compensatory verdict. The woman's case was given trial preference because she is dying of mesothelioma, and ordered jury selection to begin as soon as possible.

J&J is facing nearly 14,000 talcum powder lawsuits, each raising a common allegation that asbestos exposure from the company’s talc-based products causes ovarian cancer or mesothelioma. Hon. Freda L. Wolfson, U.S.D.J., and Hon. Lois H. Goodman, U.S.M.J., is presiding over all J&J's talcum powder multidistrict litigation (MDL No. 2738; In Re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation) in the District of New Jersey.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!